Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials-Reference-Cited by-同舟云学术

Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Published:2024-07 Issue: Volume:222 Page:121-130
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Moiz Areesha,Levett Jeremy Y.,Filion Kristian B.,Peri Katya,Reynier Pauline,Eisenberg Mark J.^ORCID

Funder

Fonds de Recherche du Québec - Santé

McGill University

Publisher

Elsevier BV

Reference25 articles.

1. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1–7 trials;Aroda;Diabetes Metab,2019

2. United States Food and Drug Administration. FDA approves new drug treatment for chronic weight management, first since 2014. Available at:https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014. Accessed on October 23, 2024.

3. Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis;Arastu;Int J Clin Pharm,2022

4. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: a systematic review and meta-analysis of randomized controlled trials;Gao;Front Pharmacol,2022

5. Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis;Tan;J ASEAN Fed Endocr Soc,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Supporting the treatment of obesity;Drug and Therapeutics Bulletin;2024-09-06

2. GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review;eClinicalMedicine;2024-09

3. Exposure to GLP‐1 receptor agonists in early pregnancy did not increase the risk of congenital malformations;Acta Paediatrica;2024-08-29

4. In vivo Antibody Painting for Next Generation Weight Loss Drugs;2024-08-23